H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on Generate Biomedicines to $25 from $16 and keeps a Buy rating on the shares. The company's GB-0895 is advancing in Phase 3 development, it has two oncology programs entering patient dosing, and a cash runway into the first half of 2028, the analyst tells investors in a research note.
